141 related articles for article (PubMed ID: 7364528)
1. Influence of hepatic and renal disorders on the pharmacokinetics of sulfachloropyridacine.
Mariño EL; Dominguez-Gil A; Tabernero JM; Macias JG
Int J Clin Pharmacol Ther Toxicol; 1980 Jan; 18(1):10-4. PubMed ID: 7364528
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of sulfachlorpyridazine].
Mariño EL; Tabernero JM; Macías JG; Domínguez-Gil A; de Castro S
Arch Farmacol Toxicol; 1979 Apr; 5(1):57-71. PubMed ID: 475478
[No Abstract] [Full Text] [Related]
3. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.
D'Incalci M; Rossi C; Zucchetti M; Urso R; Cavalli F; Mangioni C; Willems Y; Sessa C
Cancer Res; 1986 May; 46(5):2566-71. PubMed ID: 3697995
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model.
Stoeckel K; Koup JR
Am J Med; 1984 Oct; 77(4C):26-32. PubMed ID: 6093514
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction.
Hebert MF; Smith HE; Marbury TC; Swan SK; Smith WB; Townsend RW; Buell D; Keirns J; Bekersky I
J Clin Pharmacol; 2005 Oct; 45(10):1145-52. PubMed ID: 16172179
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
7. Disposition kinetics of amikacin in patients with renal impairment after intramuscular administration.
Lanao JM; Dominguez-Gil A; Tabernero JM; Molina HD
Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):271-5. PubMed ID: 7107075
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
10. Disposition of cefadroxil administered orally to rabbits with experimentally induced renal impairment.
Mariño EL; Pajares M; Dominguez-Gil AA; Cepeda M; Dominguez-Gil A
Arzneimittelforschung; 1981; 31(9):1459-61. PubMed ID: 7197955
[TBL] [Abstract][Full Text] [Related]
11. Dosage regimen of ranitidine in patients with renal impairment.
Ebihara A; Ohashi K; Ikeda T; Yuhara M; Tagawa H; Yamakado M; Asano Y; Tabei K; Nakazawa K; Kondo K
Int J Clin Pharmacol Res; 1989; 9(1):1-7. PubMed ID: 2707920
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic profile of benoxaprofen in subjects with normal and impaired renal function, prediction of multiple-dose kinetics.
Brogard JM; Comte F; Madon M; Spach MO
Eur J Rheumatol Inflamm; 1982; 5(2):113-23. PubMed ID: 7084275
[TBL] [Abstract][Full Text] [Related]
13. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
Wagner T; Heydrich D; Bartels H; Hohorst HJ
Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of naproxen in healthy volunteers and in patients with diabetic microangiopathy.
Calvo MV; Dominguez-Gil A; Miralles JM; de Pablo F
Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):486-91. PubMed ID: 528094
[TBL] [Abstract][Full Text] [Related]
15. Independent of etozolin elimination of kidney function. Single dose experiments in patients with renal insufficiency.
Knauf H; Hasenfuss G; Wais U; Schollmeyer P; Mutschler E
Arzneimittelforschung; 1980; 30(10):1791-3. PubMed ID: 7192116
[TBL] [Abstract][Full Text] [Related]
16. [Protein binding of sulphachlorpiridacine (author's transl)].
Mariño EL; Tabernero JM; Macías JG; Domínguez-Gil A; de Castro S
Arch Farmacol Toxicol; 1979 Aug; 5(2):107-16. PubMed ID: 533316
[No Abstract] [Full Text] [Related]
17. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
18. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
[TBL] [Abstract][Full Text] [Related]
19. Influence of renal dysfunction on warfarin plasma protein binding.
Bachmann K; Shapiro R; Mackiewicz J
J Clin Pharmacol; 1976 Oct; 16(10 Pt 1):468-72. PubMed ID: 977790
[TBL] [Abstract][Full Text] [Related]
20. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient.
Yogaratnam D; Miller MA; Smith BS
Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
